So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
Ascentage Pharma soars on deal with cancer drug competitor
The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
RELATED ARTICLES
-
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
-
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
CIG’s strong profit forecast fails to excite, hinting at fading AI euphoria
6166.HK603038.SHG
